6 assets in Vaginal Carcinoma

Therapeutic assets addressing Vaginal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dehydroepiandrosterone Vaginal Carcinoma	Ohio State University Comprehensive Cancer Center	P2	CCC (52)
Cyclophosphamide Vaginal Carcinoma	HRYZ Biotech Co.	P1	CC (43)
Fludarabine Vaginal Carcinoma	HRYZ Biotech Co.	P1	CC (43)
Fludeoxyglucose Vaginal Carcinoma	Jonsson Comprehensive Cancer Center	P1	CC (43)
Hryz-T101 Vaginal Carcinoma	HRYZ Biotech Co.	P1	CC (43)
Talazoparib Vaginal Carcinoma	M.D. Anderson Cancer Center	P1	CC (43)